Invst LLC Buys 8,207 Shares of Johnson & Johnson (NYSE:JNJ)

Invst LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 394.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,290 shares of the company’s stock after acquiring an additional 8,207 shares during the quarter. Invst LLC’s holdings in Johnson & Johnson were worth $1,668,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Innealta Capital LLC bought a new position in Johnson & Johnson in the second quarter valued at approximately $27,000. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management bought a new position in Johnson & Johnson during the 3rd quarter worth about $40,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on JNJ. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada upped their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Guggenheim increased their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.40.

Johnson & Johnson Stock Down 0.2 %

JNJ opened at $149.26 on Wednesday. The stock’s fifty day simple moving average is $157.84 and its 200 day simple moving average is $156.40. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $359.35 billion, a PE ratio of 21.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm earned $2.66 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were given a $1.24 dividend. The ex-dividend date was Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.32%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.